Bioniche Recognized with Québec Biotechnology Award



    - Genesis award recognizes technology transfer and commercial success -

    BELLEVILLE, ON, March 30 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC),
a research-based, technology-driven Canadian biopharmaceutical company, today
announced that it has received a Genesis Award from the Québec biotechnology,
health technology and life science industry. The "Transfer-Emergence" award
was presented to the Company last night in Montréal as part of the BIOMEDEX
2007 convention-exhibition.
    This award is given to a company and its founding officers who have
successfully implemented a technology transfer process and whose technology is
characterized by innovation. Additionally, the company must:

    
    -  be experiencing commercial success, or showing considerable potential
       that is borne out by its licensing agreements or alliances;
    -  have extensive managerial, financial and scientific expertise;
    -  have transferred technology that is derived from a Canadian government
       or university.
    

    "We are honoured to have received this award from the Québec
biotechnology industry," said Mr. Graeme McRae, President & CEO of Bioniche
Life Sciences Inc. "It recognizes the significant achievements made by our
company in the last year, with the initiation of our Phase III clinical trial
with our proprietary Mycobacterial Cell Wall-DNA Complex (MCC) in human
bladder cancer and the authorization of our E. coli O157:H7 food safety cattle
vaccine for Canadian distribution."
    Bioniche Life Sciences Inc. has had a presence in Québec since 1997, when
it set up research and development laboratories in Montréal. The Company's
human health business unit, Bioniche Therapeutics Limited, is based there.
Approximately 40 employees work in pre-clinical and clinical research, and
manufacturing.

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
185 skilled personnel and has three operating business units: Human Health,
Animal Health, and Food Safety. The Company's primary goal is to develop
proprietary cancer therapies supported by revenues from marketed products in
human and animal health. For more information, please visit www.Bioniche.com.

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159EF




For further information:

For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058 ext. 1250, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com

Organization Profile

Telesta Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890